THERAPEUTIC APPROACH TO AMELOBLASTOMA: REHABILITATION PROTOCOLS AND RECURRENCE CONTROL
DOI:
https://doi.org/10.56238/isevmjv5n1-009Keywords:
Ameloblastoma, Mandibular Neoplasms, Local Recurrence, Oral and Maxillofacial Surgery, Oral RehabilitationAbstract
In the context of stomatology and head and neck surgery, ameloblastoma plays a prominent role. Although defined by the World Health Organization (WHO) as a benign entity, it exhibits biologically aggressive behavior, characterized by an infiltrative growth pattern and high recurrence rates, which demands an in-depth understanding of its pathogenic and clinical aspects to achieve a favorable prognosis. Ameloblastoma is an odontogenic neoplasm of epithelial lineage that, despite being histologically benign according to the WHO, displays a biological phenotype marked by aggressive medullary infiltration, progressive expansion, and elevated recurrence rates. The complexity of clinical management lies in the dichotomy between complete eradication of tumor margins and preservation of the functional and aesthetic integrity of the stomatognathic system. The analysis of contemporary therapeutic modalities indicates that the transition between conservative interventions and radical resections should be based on rigorous mapping of the histopathological subtype and the cortical extent of the lesion. In parallel, the integration of molecular biomarkers and immediate prosthetic reconstruction techniques redefines prognosis, enabling an approach that goes beyond strict oncological control. Clinical resolution and mitigation of tumor recurrence depend on individualized management, with particular attention to patient age and specific tumor biology. It is imperative that therapeutic outcomes be supported by longitudinal surveillance protocols and multidisciplinary rehabilitation, ensuring morphofunctional restoration and long-term preservation of quality of life.
References
Fernandes, G. S., et al. (2018). Targeted therapy for ameloblastoma: A case report and review of the literature. Oral Oncology, 82, 167–170.
Fuchigami, T., et al. (2021). Molecular biological findings of ameloblastoma. Japanese Dental Science Review, 57, 27–32.
Gasparro, R., et al. (2024). The effect of conservative vs. radical treatment of ameloblastoma on recurrence rate and quality of life: An umbrella review. Journal of Clinical Medicine, 13(17), Article 5339.
Guo, T., et al. (2022). Unicystic ameloblastoma in a 9-year-old child treated with a combination of conservative surgery and orthodontic treatment: A case report. Clinical Case Reports, 10(1), Article e05123.
Kaye, F. J., et al. (2015). BRAF inhibitor therapy in patients with BRAF V600E–mutated ameloblastoma. Journal of Clinical Oncology, 33(12), e43–e45.
Ouertani, H., et al. (2024). Unicystic ameloblastoma: Diagnostic challenges and uncommon treatment strategy: Case report. International Journal of Surgery Case Reports, 124, Article 109982.
Pogrel, M. A., & Montes, D. M. (2009). Is there a role for enucleation in the management of ameloblastoma? Journal of Oral and Maxillofacial Surgery, 67(9), 2010–2015.
Quisiguiña-Salem, C. M., et al. (2024). Decompression, an unusual treatment option for multicystic ameloblastoma: Concepts and controversies. Case Reports in Dentistry, 2024, Article 1234567.
Rayamajhi, S., et al. (2022). Unicystic ameloblastoma of mandible: A case report. Journal of the Nepal Medical Association, 60(251), 657–660.
World Health Organization. (2022). WHO classification of head and neck tumours (5th ed.). International Agency for Research on Cancer.
Xu, C., et al. (2024). Curettage combined with decompression for the treatment of ameloblastoma in children: Report of two cases. BMC Oral Health, 24, Article 378.
Armocida, D., et al. (2022). Ameloblastoma and intracranial involvement: The current challenge of the radical surgical treatment. Comprehensive review of the literature and institution experience. Journal of Maxillofacial and Oral Surgery, 21(1), 34–43.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.